Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032352 · ClinicalTrials.gov registry record
Predictive Assay for Decision Making in Adjuvant Therapy
A clinical trial, sponsored by Insight Molecular Diagnostics.
- Terminated
- Registry status
- 55
- Enrollment target
NCT05032352: Clinical Trial study, sponsored by Insight Molecular Diagnostics.
NCT05032352 is a clinical trial that was terminated before completion, run by Insight Molecular Diagnostics. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05032352 was terminated before completion, sponsored by Insight Molecular Diagnostics.
- TERMINATED
- Registry status
- 55 participants
- Enrollment target
Study Summary
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor \< or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay DetermaRx being Considered for Adjuvant Platinum-based chemotherapy or other adjuvant therapy versus Observation
Primary Outcome
To compare Disease Free Survival (DFS) in patients with resected, stage I or IIA non-squamous NSCLC found to be at HIGH/INTERMEDIATE Risk by DetermaRX choosing to undergo adjuvant therapy using a platinum-based doublet or other adjuvant therapy versus observation.
Interventions
- OTHER Observation
- DRUG Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2022-10-28 |
Why NCT05032352 stopped before completion
NCT05032352 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.
NCT05032352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05032352 about?
NCT05032352 is a clinical study titled "Predictive Assay for Decision Making in Adjuvant Therapy". Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor \< or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay DetermaRx being Considered for ...
What is the current status of trial NCT05032352?
This trial is currently terminated. The enrollment target is 55 participants. The study started on 2022-01-28. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05032352?
The interventions under investigation include: Observation (OTHER), Adjuvant (DRUG).
Who is sponsoring clinical trial NCT05032352?
This trial is sponsored by Insight Molecular Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI